# Semaglutide for Cocaine Use Disorder in HIV Cohort (Phase 2)

**Type:** Clinical trial  
**Phase:** 2  
**Status:** Recruiting (as of May 2026)  
**Intervention:** Semaglutide vs. placebo  
**Population:** Adults with cocaine use disorder, with and without HIV infection  
**Primary objective:** Safety and effectiveness of semaglutide for CUD  
**Special population rationale:** High CUD prevalence in HIV+ individuals; dual metabolic and addiction benefits  
**Registry:** withpower.com/trial/phase-2-human-immunodeficiency-virus-hiv-infections-2-2025

## Timeline

- **2025-02** — Trial opened for recruitment
- **2026-05** — Actively recruiting participants

## Context

This trial targets a high-need population where CUD prevalence is elevated and metabolic complications are common. The HIV-specific design provides real-world justification for off-label use even before CUD-specific approval. Follows All of Us observational signal (OR=0.25 for CUD in GLP-1 users).

## Expected Results

Phase 2 results anticipated 2027-2028.